239 related articles for article (PubMed ID: 17136111)
21. [Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].
Massy ZA; Maizel J
Nephrol Ther; 2014 Nov; 10(6):441-50. PubMed ID: 25070605
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of hyperphosphatemia with sevelamer in patients with chronic renal failure].
Suñer M; Guerrero A; Montes R; Rivera M; Ruiz A; Martínez-García M; Pérez-Valdivia MA; Mateos J
Nefrologia; 2004; 24(2):142-8. PubMed ID: 15219089
[TBL] [Abstract][Full Text] [Related]
23. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
Marangon N; Lindholm B; Stenvinkel P
Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
25. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
[TBL] [Abstract][Full Text] [Related]
27. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
28. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
29. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
Assimon MM; Mousa S; Shaker O; Pai AB
Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic potential of novel phosphate binders.
Querfeld U
Pediatr Nephrol; 2005 Mar; 20(3):389-92. PubMed ID: 15650884
[TBL] [Abstract][Full Text] [Related]
31. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
[No Abstract] [Full Text] [Related]
32. [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].
Sesso R; Ferraz MB
Rev Assoc Med Bras (1992); 2003; 49(1):103-8. PubMed ID: 12724821
[TBL] [Abstract][Full Text] [Related]
33. Emerging effects of sevelamer in chronic kidney disease.
Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
35. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
37. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Hanba Y; Masumoto A; Moribata M; Shigemathu T
Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
[TBL] [Abstract][Full Text] [Related]
38. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
39. The phosphate binder equivalent dose.
Daugirdas JT; Finn WF; Emmett M; Chertow GM;
Semin Dial; 2011; 24(1):41-9. PubMed ID: 21338393
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
